Clinical trials: Viral Pneumonia
COVID-19
The Immunogenicity, Safety, and Effectiveness of the COVID-19 Inactivated Vaccine
To fast respond the coronavirus disease of 2019 (COVID-19) pandemic, the Indonesian government has launched "Vaksinasi Gotong Royong" (a mutual cooperation vaccination program) in which any company/legal entity/business entity…
- Trial name
- NCT05126550
- Testing
- SARS-CoV-2 vaccine (Vero cell) inactivated
- Where
- 4 sites in Indonesia
- Volunteers
- 435 people, healthy volunteers welcome
- Sponsor
- PT. Kimia Farma (Persero) Tbk
COVID-19
A Study To Assess The Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19
This is a randomized, double-blind, placebo-controlled Phase 2 study in participants over the age of 18 years with mild COVID-19.
- Trial name
- NCT05713318
- Testing
- HH-120 nasal spray
- Where
- 16 sites in China
- Volunteers
- 200 people
- Sponsor
- Huahui Health
SARS-CoV-2
COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease
Primary Objectives Phase 1 (Safety and Tolerability) Evaluate the safety and tolerability of REGN14256+imdevimab and REGN14256 monotherapy, as measured by treatment-emergent adverse events (TEAEs), injection-site reactions…
- Trial name
- NCT05081388
- Testing
- REGN14256, imdevimab, casirivimab + imdevimab
- Where
- 28 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients
The trial is randomized, blinded, two arms, active comparator controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in combination with standard care as per hospital practice versus standard care alone…
- Trial name
- NCT04347174
- Testing
- Suspension of heat killed (autoclaved) Mycobacterium w
- Where
- 4 sites in India
- Volunteers
- 40 people
- Sponsor
- Cadila Pharnmaceuticals
Mild-to-Moderate COVID-19
A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function
This exploratory, open-label clinical study aims to explore the physiologic effects of KB109, a novel glycan, on adult patients with COVID-19 illness on gut microbiota structure and function in the outpatient setting.
- Trial name
- NCT04486482
- Testing
- KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
- Where
- 12 sites in United States
- Volunteers
- 49 people
- Sponsor
- Kaleido Biosciences
COVID-19, SARS-CoV-2 Infection
A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster
A observer-blind, randomized, controlled, investigator-initiated clinical trial to evaluate the safety and immunogenicity of a booster vaccination with Recombinant COVID-19 vaccine (Sf9 Cell) in a population aged 18-60 years old…
- Trial name
- NCT06381843
- Testing
- Recombinant COVID-19 Vaccine (Sf9 Cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19, SARS-CoV-2
Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study)
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- SUPERNOVA (NCT05648110)
- Testing
- AZD5156 (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort)
- Where
- 215 sites in United States, Australia and 16 more
- Volunteers
- 3,882 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
SARS-CoV-2
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
This was a phase II, randomized, placebo-controlled, observer-blinded study of the safety and immunogenicity of SARS-CoV-2 messenger RNA (mRNA) vaccine (BNT162b2) in Chinese healthy population.
- Trial name
- NCT04649021
- Testing
- BNT162b2
- Where
- China
- Volunteers
- 960 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Beta-glucans for Hospitalised Patients With COVID-19
This randomised trial aims to assess the role of beta1-3 glucan supplementation in improving clinical symptoms and other outcomes amongst hospitalised patients with COVID-19.
- Trial name
- NCT05465798
- Testing
- MC 3x3
- Where
- Chile
- Volunteers
- 60 people
- Sponsor
- Wohlstand Pharmaceutical
Stroke, Acute, COVID-19
EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study During the COVID-19 Pandemic ( EPISODEPSCOVID )
Prehospital providers encounter patients with suspected stroke frequently. Stroke and COVID-19 are related potentially putting these healthcare workers at risk of COVID-19 infection.
- Trial name
- EPISODE-PH-COV (NCT04445493)
- Testing
- MindRhythm Harmony
- Where
- United States
- Volunteers
- 486 people
- Sponsor
- MindRhythm, Inc.
SARS-CoV-2 Infection (COVID-19)
A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)
To assess the efficacy and safety of FOY-305 in patients with SARS-CoV-2 infection (COVID-19) in a placebo-controlled, multicenter, double-blind, randomized, parallel-group comparative study.
- Trial name
- NCT04657497
- Testing
- FOY-305
- Where
- 25 sites in Japan
- Volunteers
- 155 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
COVID-19, SARS-CoV-2 Infection
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Corona Virus Infection
- Trial name
- NCT05037097
- Testing
- ARCT-165, ARCT-154, ARCT-021
- Where
- 4 sites in United States, Singapore and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
Respiratory Failure, ARDS
Plasma Adsorption in Patients With Confirmed COVID-19
To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients admitted to the ICU.
- Trial name
- NCT04358003
- Testing
- Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
- Where
- 7 sites in United States
- Volunteers
- 107 people
- Sponsor
- Marker Therapeutics AG
Covid19, SARS CoV-2
Capturing Infectious COVID-19 Asymptomatic Cases in Singapore
This study is being conducted to assess the performance of the BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2, used in serial testing, in identification of infectious, asymptomatic individuals.
- Trial name
- NCT04812327
- Testing
- BD Veritor Plus System for Rapid Detection of SARS CoV-2, rt-PCR, viral culture
- Where
- Singapore
- Sponsor
- Becton, Dickinson and Company
Long COVID, Post-COVID Syndrome
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
- Conditions
- Long COVID, Post-COVID Syndrome, Post COVID-19 Condition
- Trial name
- NCT05682560
- Testing
- REGENECYTE
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- StemCyte, Inc.
COVID-19
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus…
- Trial name
- NCT05706324
- Testing
- Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
COVID-19, Coronavirus
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- COViNOX (NCT04421508)
- Testing
- INOpulse
- Where
- 17 sites in United States
- Volunteers
- 191 people
- Sponsor
- Bellerophon Pulse Technologies
COVID-19
A Bridging Study of FB2001 in Healthy Subjects
In the first human clinical trial conducted in the United States, single and multiple dosing of FB2001 in multiple dose groups were partially completed，and FB2001 demonstrated good safety and tolerability.
- Trial name
- NCT05197179
- Testing
- FB2001
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Frontier Biotechnologies Inc.
COVID-19
Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)
This study will assess the safety, immunogenicity and efficacy of AG0302-COVID19 in healthy adult volunteers.
- Trial name
- NCT04655625
- Testing
- Group A (AG0302-COVID19), Group B (AG0302-COVID19)
- Where
- 8 sites in Japan
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- AnGes, Inc.
Covid 19, Influenza
Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza
2. Participants will: Take nitazoxanide 600mg (or placebo) orally twice daily for 7 days, for a total of 14 doses. Visit the clinic on the 7th day of treatment for a check-up and safety tests.
- Trial name
- NCT06817096
- Volunteers
- 340 people
- Sponsor
- Azidus Brasil
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.